StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) from a hold rating to a sell rating in a report published on Wednesday.
Several other equities analysts have also weighed in on the company. Chardan Capital reissued a "buy" rating and set a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reiterated a "buy" rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a report on Thursday, October 24th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $5.08.
View Our Latest Stock Report on MCRB
Seres Therapeutics Stock Performance
MCRB traded up $0.04 during midday trading on Wednesday, reaching $0.92. The company had a trading volume of 1,663,547 shares, compared to its average volume of 4,337,181. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $2.05. The business has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.90. The stock has a market cap of $156.23 million, a PE ratio of -3.81 and a beta of 2.06.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in MCRB. Virtu Financial LLC lifted its holdings in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after buying an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC increased its holdings in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after acquiring an additional 22,250 shares during the period. State Street Corp lifted its stake in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. Point72 DIFC Ltd bought a new position in Seres Therapeutics in the 2nd quarter valued at $64,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Seres Therapeutics in the 2nd quarter valued at $92,000. Institutional investors own 59.34% of the company's stock.
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
